In a phase 2 trial, the association of dabrafenib and trametinib was assessed in first line treatment of BRAF p.Val600Glu metastatic NSCLC and showed an ORR of 64% [56]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.